EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Short‐Term Cardiac and Metabolic Safety of Propranolol Therapy in Infants With Infantile Hemangiomas: A Retrospective Real‐World Study

Hubert Arasiewicz, Michal Dec, Tomasz Galina, Zofia Kampka, Malgorzata Kowalska

Dermatologic Therapy · 2026-01 · 2026 (1)

DOI: 10.1155/dth/2392830 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Dermatologic Therapy, online erschienen am 26.06.2026. Verfasst von Hubert Arasiewicz und 4 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Propranolol is widely used in infants with infantile hemangiomas (IHs); however, its cardiac safety and tolerance in early infancy remain incompletely characterized, particularly with respect to conduction intervals and ventricular repolarization. Clinical data describing real‐world electrocardiographic (ECG) responses to propranolol in this population remain limited. This study evaluated short‐term cardiac and metabolic safety using paired ECG and laboratory assessments.

Methods

A retrospective follow‐up study was performed in infants with IH treated with propranolol (1–2 mg/kg/day) at a tertiary pediatric dermatology and vascular anomalies center. Standard 12‐lead ECGs were obtained at baseline ( T 0 ) and at 4–6 weeks ( T 1 ). Heart rate, rhythm, PQ interval, QRS duration, QT interval, QTc (Bazett and Fridericia), and arrhythmias were analyzed. Metabolic tests included the measurement of glucose, liver enzymes, creatinine, and bilirubin. Paired comparisons were made using parametric or nonparametric tests as appropriate.

Results

Of 155 infants treated with propranolol, 90 had baseline ECGs and 79 had follow‐up ECGs. Due to variability in data availability, paired analyses were performed in smaller subgroups depending on the parameter assessed. All infants with available ECG recordings exhibited sinus rhythm at T 0 ; sinus rhythm persisted in all but two at T 1 , and no clinically significant arrhythmias occurred. PQ, QRS, and QT intervals remained stable between T 0 and T 1 ; median QT was 260 ms at both assessments, with no significant change in Wilcoxon testing. QT and QTc remained stable; subgroup differences reflected the expected heart rate dependence. No atrioventricular block, intraventricular conduction disturbance, or clinically relevant QT prolongation was observed. Metabolic parameters remained within pediatric reference ranges, and no hypoglycemia occurred.

Conclusions

Propranolol at therapeutic doses demonstrated favorable short‐term cardiac and metabolic tolerance in infants with IH. Detailed ECG analysis confirmed stable conduction and repolarization parameters without clinically relevant arrhythmias or QT prolongation. These findings support a selective rather than universal ECG screening approach in otherwise healthy infants without identifiable cardiac risk factors.

Zitieren

APA

Arasiewicz, H., Dec, M., Galina, T., Kampka, Z., & Kowalska, M. (2026). Short‐Term Cardiac and Metabolic Safety of Propranolol Therapy in Infants With Infantile Hemangiomas: A Retrospective Real‐World Study. Dermatologic Therapy, 2026(1). https://doi.org/10.1155/dth/2392830

Vancouver

Arasiewicz H, Dec M, Galina T, Kampka Z, Kowalska M. Short‐Term Cardiac and Metabolic Safety of Propranolol Therapy in Infants With Infantile Hemangiomas: A Retrospective Real‐World Study. Dermatologic Therapy. 2026;2026(1). doi:10.1155/dth/2392830

BibTeX
@article{Arasiewicz2026,
  author = {Arasiewicz, Hubert and Dec, Michal and Galina, Tomasz and Kampka, Zofia and Kowalska, Malgorzata},
  title = {Short‐Term Cardiac and Metabolic Safety of Propranolol Therapy in Infants With Infantile Hemangiomas: A Retrospective Real‐World Study},
  journal = {Dermatologic Therapy},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/dth/2392830}
}
Kostenlos starten →